Alzheimer’s Drug Hope Hits a Wall

Big news: two promising Alzheimer’s drugs just got rejected for NHS use because the benefits don’t justify the sky-high price tag. Even though donanemab and lecanemab can slow early Alzheimer’s, the health watchdog says the gains are just too small for the cost (think: £500 million+ a year!). Charities are calling it a painful setback, and patients now face a long wait unless they can pay privately. Science is racing ahead, but the system just can’t keep up. #Alzheimers #NHS #HealthNews